Edition:
India

Global Blood Therapeutics Inc (GBT.OQ)

GBT.OQ on NASDAQ Stock Exchange Global Select Market

61.19USD
1:30am IST
Change (% chg)

$-1.71 (-2.72%)
Prev Close
$62.90
Open
$63.27
Day's High
$63.34
Day's Low
$60.80
Volume
137,420
Avg. Vol
297,701
52-wk High
$87.50
52-wk Low
$39.96

Select another date:

Wed, Jun 24 2020

BRIEF-GBT Announces Plans To Seek Regulatory Approval For Oxbryta To Treat Sickle Cell Patients In Europe

* GBT ANNOUNCES PLANS TO SEEK REGULATORY APPROVAL FOR OXBRYTA® (VOXELOTOR) TO TREAT SICKLE CELL PATIENTS IN EUROPE

Global Blood Therapeutics to seek to expand label for sickle cell treatment

Global Blood Therapeutics Inc said on Monday it plans to ask U.S. regulators to greenlight the use of its sickle cell treatment, Oxbryta, in children aged 4 to 11, expanding on an earlier approval for patients 12 and over.

UPDATE 1-Global Blood Therapeutics to seek to expand label for sickle cell treatment

June 8 Global Blood Therapeutics Inc said on Monday it plans to ask U.S. regulators to greenlight the use of its sickle cell treatment, Oxbryta, in children aged 4 to 11, expanding on an earlier approval for patients 12 and over.

BRIEF-Gbt Plans To Seek Expanded Labeling For Oxbryta® For Sickle Cell Disease

* GBT ANNOUNCES PLANS TO SEEK EXPANDED LABELING FOR OXBRYTA® (VOXELOTOR) TO TREAT CHILDREN AGES 4 TO 11 YEARS WITH SICKLE CELL DISEASE

BRIEF-Global Blood Therapeutics Appointed Deval Patrick To Board As Director

* GLOBAL BLOOD THERAPEUTICS INC - ON MAY 28, APPOINTED DEVAL L. PATRICK TO BOARD AS A CLASS III DIRECTOR

Select another date: